Swiss researchers may have finally found an effective second-line treatment for mesothelioma. Scientists with the Swiss Group for Clinical Cancer Research presented their findings at the recent European Society for Medical Oncology conference in Barcelona. Mesothelioma patients who fail after first-line therapy have few options. The new study focused on lurbinectedin, a drug that impacts cancer cells at the DNA level. Early studies suggest lurbinectedin might make a good second-line treatment for small cell lung cancer. According to the Swiss team, more than half of patients in their study responded to lurbinectedin as a second-line treatment for mesothelioma. In Search of a Second-Line Mesothelioma Treatment Malignant mesothelioma is notoriously difficult to diagnose and even harder to treat. It is usually … Continue reading Second-Line Treatment for Mesothelioma with Lurbinectedin
More than half of patients who have peritoneal mesothelioma surgery with HIPEC develop problems with their blood cells afterward. That’s the finding of a team of cancer researchers from Singapore. The group analyzed 15 years worth of data on peritoneal mesothelioma surgery outcomes. They found that, even though the procedure saves lives, it can be risky. Older patients and those who had prior chemotherapy were most likely to develop hematological toxicities after peritoneal mesothelioma surgery. Hematological Toxicities and Mesothelioma Treatment Hematological toxicities are problems with the cells that make up the blood. This can include white blood cells, red blood cells, platelets, and proteins involved in bleeding and clotting. Several drugs that kill mesothelioma cells can cause blood cell problems. … Continue reading Peritoneal Mesothelioma Surgery with HIPEC Can Trigger Blood Cell Problems
The powerful CRISPR gene editing technique might have a role to play in the future of mesothelioma treatment. CRISPR is a method for altering certain genes to help fight disease. This week, scientists at the University of Pennsylvania released data from the first study of CRISPR in US cancer patients. It was only a safety study, but the results are promising. They could have wide-ranging implications for patients fighting aggressive cancers like malignant mesothelioma. Modifying Genes To Help Fight Cancer The CRISPR gene editing technique is a simplified version of the method bacteria cells use to defend themselves against viruses. This antiviral defense system is called CRISPR-Cas9. The new Penn Medicine study involved just three cancer patients. Two of the … Continue reading CRISPR Gene Editing Technique and the Future of Mesothelioma Treatment
Can repeated mesothelioma surgeries extend peritoneal mesothelioma survival? A new case report out of Japan suggests the answer may be yes. The article recounts the case of a patient with peritoneal mesothelioma. Each time surgeons removed a mesothelioma tumor, a new one would occur in a different location. The man had four separate mesothelioma surgeries over the course of five years. Repeated mesothelioma surgeries are not the norm. But this treatment approach may be the reason for the man’s unusually long mesothelioma survival. Surgical Treatment of Peritoneal Mesothelioma Peritoneal mesothelioma accounts for about 20 percent of mesothelioma cases in the US each year. It occurs on the membrane that surrounds the abdominal organs. Because it sits so close to these … Continue reading Repeated Mesothelioma Surgeries Credited with Japanese Man’s Survival
A new UK study points to some of the potential challenges and benefits for patients involved in mesothelioma clinical trials. Researchers at three teaching hospitals in England interviewed mesothelioma patients who took part in the Mesothelioma and Radical Surgery (MARS 2) trial. The trial compared outcomes in people who had a combination of surgery and chemotherapy with those who only had chemotherapy. The findings show that not all aspects of mesothelioma clinical trials are positive for patients. A Study Within a Study Pleural mesothelioma is a fast-growing cancer that starts on the lining around the lungs. Asbestos exposure is usually the cause. With standard cancer treatments, most mesothelioma patients face a poor prognosis. Mesothelioma often leads to death within a … Continue reading Mesothelioma Clinical Trials: Study Highlights Challenges for Patients
A new report contains some hopeful news about biphasic mesothelioma survival. Biphasic mesothelioma is the rarest subtype of a rare cancer. It is also the subtype that is hardest to treat. Biphasic mesothelioma survival is typically shorter than other subtypes. But Italian researchers say, with the right combination of mesothelioma treatments, patients with this subtype can achieve long-term survival. Subtypes and their Impact on Biphasic Mesothelioma Survival All pleural mesothelioma tumors grow on the membrane that surrounds the lungs. When this membrane is healthy, it is flexible and expands naturally with each breath. When a mesothelioma tumor grows on this membrane, it can restrict the lungs and make it hard to breathe. As tumors grow, mesothelioma can spread to other … Continue reading Biphasic Mesothelioma Survival Possible in Select Patients
New research suggests that it may be possible to predict which mesothelioma patients are at risk for opioid addiction. The research comes from the University of California. Scientists analyzed more than a hundred thousand cancer cases to come up with a list of risk factors for opioid addiction. The information could help doctors select other, less dangerous ways of managing pain in high risk mesothelioma patients. Mesothelioma Pain and Opioid Addiction Chest pain is a symptom of pleural mesothelioma. People with peritoneal mesothelioma may experience abdominal pain. As the disease progresses or lung fluid builds up, that pain can impact quality of life. Many mesothelioma patients also experience pain after surgery. Managing pain is a significant part of care for … Continue reading Predicting Opioid Addiction in Mesothelioma Patients
There has been a setback for researchers focused on the promise of pembrolizumab for mesothelioma. New research suggests that pembrolizumab (Keytruda) may not be the miracle mesothelioma drug that some were hoping for. The Phase III trial results were presented at a the European Society of Medical Oncology conference now underway in Spain. They suggest that pembrolizumab for mesothelioma may be no better than chemotherapy for improving survival. Pembrolizumab for Mesothelioma: How it Works Malignant pleural mesothelioma is a rare but lethal cancer. It is usually associated with on-the-job asbestos exposure. There is no cure. The only drug approved for mesothelioma treatment is Alimta (pemetrexed). Cancer researchers around the world are working hard to find other mesothelioma treatments. Pembrolizumab for … Continue reading Pembrolizumab for Mesothelioma Dealt Setback by New Trial Results
Cancer researchers in New York are exploring the concept of using step counts for cancer prognosis. If further studies back it up, the technique might help predict outcomes for people with mesothelioma. The new study involved people with non-small cell lung cancer. The patients wore commercial fitness trackers so doctors could see how much they walked. The researchers compared step levels with treatment outcomes. They concluded that there is value to using step counts for cancer prognosis. It may even be more effective than some more traditional methods for predicting survival. Cancer Prognosis and Chemoradiotherapy Mesothelioma survival usually depends on how well patients respond to standard treatments. Healthier, more active cancer patients tend to have better outcomes. Chemotherapy and radiation … Continue reading Step Counts for Cancer Prognosis: Could it Work for Mesothelioma?
There is new evidence supporting the use of low-dose aspirin for cancer survival. The evidence comes from two new retrospective studies. The first involved patients with head and neck cancer. The second focused on patients with early-stage non-small cell lung cancer (NSCLC). NSCLC is similar to mesothelioma in many ways. Mesothelioma is an aggressive cancer that is often fatal within a year of diagnosis. Based on the new findings, some mesothelioma patients may consider talking to their doctors about aspirin for cancer survival Anti-Inflammatories and Cancer Treatment Anti-inflammatory drugs like aspirin can cut the risk for heart disease and heart attack. But research led by the Roswell Park Cancer Center shows they may have similar benefits for people with cancers … Continue reading Should Mesothelioma Patients Take Aspirin for Cancer Survival?